Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CNP 106

Next Previous
Drug Profile

CNP 106

Alternative Names: CNP-106; CNP-MYG

Latest Information Update: 07 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cour Pharmaceutical Development
  • Class
  • Mechanism of Action Immunomodulators; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Myasthenia gravis

Most Recent Events

  • 01 Oct 2025 CNP 106 receives Orphan Drug status for Myasthenia gravis in USA
  • 09 Feb 2023 Phase-I/II clinical trials in Myasthenia gravis in USA, prior to February 2023 (IV) (Cour Pharmaceuticals pipeline, February 2023)
  • 25 Oct 2022 COUR Pharmaceuticals plans a phase Ib/IIa trial for Myasthenia gravis (MG) in the first quarter of 2023 ,

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top